Counterfeit versions of Novo Nordisk’s Ozempic are becoming more of a concern, both for the company and to global authorities. Lars Fruergaard Jørgensen, the Danish drugmaker’s CEO, told Reuter’s the company is currently working alongside authorities in multiple countries to navigate the issue.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
